Current time in Korea 01:59 Nov 01 (Sun) Year 2020 KCS KCS Publications
KCS Publications
My Journal  Log In  Register
HOME > Search > Browsing(JKCS) > Archives

Journal of the Korean Chemical Society (JKCS)

ISSN 1017-2548(Print)
ISSN 2234-8530(Online)
Volume 49, Number 3
JKCSEZ 49(3)
June 20, 2005 

Monitoring of the Optical Purity for Dexibuprofen by HPLC

HPLC에 의한 Dexibuprofen의 광학순도 모니터링
Jae Jeong Ryoo*, Mi-kyeong Jeon, Kyu Seong Huh, Jeong-A Kim, Jeong Gu Hwang, Gwi Im Mun, Hyeon Suk Oh

류재정*, 전미경, 허규성, 김정아, 황정구, 문귀임, 오현숙
키랄 의약품, 이부프로펜, 덱시부프로펜, HPLC 분리, 상대표준편차, 광학순도 , Chiral Drugs, Ibuprofen, Dexibuprofen, HPLC Separation, Relative Standard Deviation, Optical Purity
키랄 의약품들의 두 거울상 이성질체들은 종종 서로 다른 약리작용을 보여준다. 비스테로이드계 진통소염제인 이부프로펜은 하나의 키랄 중심을 갖는 키랄 의약품으로서, (S)-이부프로펜(덱시부프로펜으로 불림)이 (R)-이성질체 보다 효과적이며, 최근 우리나라에서 이 덱시부프로펜이 상용화되었다. 본 연구에서는 Chiralcel OD 칼럼을 키랄 정지상으로 그리고 헥산, 이소프로판올, 초산의 100:1:0.1 혼합용액을 이동상으로 사용하여 국내에서 상용화된 16개의 덱시부프로펜 시료의 광학순도를 조사하였다. 실험 결과 대부분 99% 이상의 높은 광학순도를 보여주었으며, 이때 상대표준편차도 상당히 작은 값을 보였다.

Two enantiomers of chiral drugs often differ substantially in their pharmacological, toxicological pharmacokinetic profile. Ibuprofen is a nonsteroidal antiinflammatory drug (NSAID) and has a chiral center. Between the two enantiomers of ibuprofen, (S)-ibuprofen (called dexibuprofen) is more effective, and the more active dexibuprofen was commercialized in our country recently. In this study, the optical purity of sixteen commercialized dexibuprofens prepared from nine Korean drug companies were examined by an optimized chiral HPLC condition. The Chiralcel OD column was used as a chiral stationary phase and the mixed eluent of hexane, isopropanol, and acetic acid as 100 : 1 : 0.1 was used as a mobile phase with a flow rate of 1.0 mL/min. Each data was obtained from an average value of at least three different experiments for each sample and the relative standard deviation of them appeared very small. Optical purity values of most commercialized dexibuprofens used in this study were higher than 99 percents.

283 - 0
Full Text